Free Trial
NASDAQ:ENSC

Ensysce Biosciences (ENSC) Stock Price, News & Analysis

Ensysce Biosciences logo
$0.59 -0.06 (-9.20%)
(As of 11/21/2024 ET)

About Ensysce Biosciences Stock (NASDAQ:ENSC)

Key Stats

Today's Range
$0.57
$0.65
50-Day Range
$0.17
$0.73
52-Week Range
$0.14
$2.06
Volume
1.91 million shs
Average Volume
8.43 million shs
Market Capitalization
$8.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.

Ensysce Biosciences Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
1st Percentile Overall Score

ENSC MarketRank™: 

Ensysce Biosciences scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Ensysce Biosciences.

  • Earnings Growth

    Earnings for Ensysce Biosciences are expected to decrease in the coming year, from ($0.83) to ($0.85) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Ensysce Biosciences is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Ensysce Biosciences is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Ensysce Biosciences has a P/B Ratio of 1.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Ensysce Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    43.43% of the float of Ensysce Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Ensysce Biosciences has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Ensysce Biosciences has recently increased by 5,514.50%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Ensysce Biosciences does not currently pay a dividend.

  • Dividend Growth

    Ensysce Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    43.43% of the float of Ensysce Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Ensysce Biosciences has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Ensysce Biosciences has recently increased by 5,514.50%, indicating that investor sentiment is decreasing significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Ensysce Biosciences this week, compared to 1 article on an average week.
  • Search Interest

    14 people have searched for ENSC on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.
  • MarketBeat Follows

    6 people have added Ensysce Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Ensysce Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 7.90% of the stock of Ensysce Biosciences is held by insiders.

  • Percentage Held by Institutions

    Only 5.63% of the stock of Ensysce Biosciences is held by institutions.

  • Read more about Ensysce Biosciences' insider trading history.
Receive ENSC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ensysce Biosciences and its competitors with MarketBeat's FREE daily newsletter.

ENSC Stock News Headlines

Buffett Dumps $982 Million in BofA Stock—What Does He Know?
Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.
ENSC Improves Position
Ensysce Biosciences Reports Improved Financial Results
Ensysce Biosciences receives extension to demonstrate Nasdaq compliance
See More Headlines

ENSC Stock Analysis - Frequently Asked Questions

Ensysce Biosciences' stock was trading at $1.06 at the beginning of 2024. Since then, ENSC shares have decreased by 44.1% and is now trading at $0.5924.
View the best growth stocks for 2024 here
.

Ensysce Biosciences, Inc. (NASDAQ:ENSC) issued its quarterly earnings results on Tuesday, November, 12th. The company reported $0.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.30) by $0.37. The business earned $3.42 million during the quarter, compared to analyst estimates of $0.25 million. Ensysce Biosciences had a negative net margin of 179.26% and a negative trailing twelve-month return on equity of 292.81%.

Ensysce Biosciences's stock reverse split on the morning of Friday, March 31st 2023. The 1-12 reverse split was announced on Friday, March 31st 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Ensysce Biosciences' top institutional shareholders include Anson Funds Management LP (11.15%).
View institutional ownership trends
.

Shares of ENSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ensysce Biosciences investors own include Predictive Oncology (POAI), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT), Meta Platforms (META), Insulet (PODD) and Broadcom (AVGO).

Company Calendar

Last Earnings
11/12/2024
Today
11/21/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
3/21/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ENSC
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

Net Income
$-10,610,000.00
Net Margins
-179.26%
Pretax Margin
-179.26%

Debt

Sales & Book Value

Annual Sales
$2.23 million
Book Value
$0.47 per share

Miscellaneous

Free Float
12,775,000
Market Cap
$8.22 million
Optionable
Not Optionable
Beta
0.63
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:ENSC) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners